PRasugrEl Monotherapy Following prImary percUtaneous Coronary Intervention for ST-elevation Myocardial Infarction

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2268 participants.

Also called NCT05709626

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 2,268 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05709626
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05709626. Randomized; no masking; primary purpose treatment. Start 2023-04-07 (actual); primary completion 2026-02-12 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
PRasugrEl Monotherapy Following prImary percUtaneous Coronary Intervention for ST-elevation Myocardial Infarction
Acronym
PREMIUM
Condition
ST-segment Elevation Myocardial Infarction (STEMI)
Intervention (Drug)
No aspirin (Prasugurel monotherapy)
Intervention (Drug)
12-month DAPT
Lead sponsor
Kindai University (class: other)
Collaborator
Boston Scientific Corporation (class: industry)

Record details

Record id
cardio:ct-nct05709626
Content hash
ad4f335de7285eb81784be1b666d49e44e9681b0facb33fa8fe6c025cbce9eb6